GAITHERSBURG, Md., March 20, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the quarter and year ended December 31, 2017 before the market open and host a conference call on Thursday, March 29.
Conference Call Details | |||
Date: | Thursday, March 29 | ||
Time: | 8:30am Eastern Time | ||
Domestic: | 866-548-4713 | ||
International: | 323-794-2093 | ||
Conference ID: | 6280732 | ||
Webcast: | http://public.viavid.com/index.php?id=128569 | ||
Replays, Available through April 12th: | |||
Domestic: | 844-512-2921 | ||
International: | 412-317-6671 | ||
Replay PIN: | 6280732 |
About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.
Contacts:
Bill Enright
President and CEO
Phone: 240-654-1450
enright@altimmune.com
Ashley Robinson
LifeSci Advisors, LLC
617-535-7742
arr@lifesciadvisors.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.